IDRx, Inc.

Executive Summary

IDRx, Inc. is a private oncology company pioneering rationally designed combination therapies to overcome cancer resistance. Founded in 2021 and headquartered in Cambridge, MA, IDRx develops small molecule regimens that simultaneously inhibit multiple cancer-driving pathways, aiming to create more durable and potent treatments for aggressive malignancies. The company has raised $120 million to advance its pipeline of targeted combinations, which are currently in Phase 1 clinical development. Its lead programs focus on genetically defined cancers where resistance mechanisms are well-characterized, positioning IDRx to address high unmet needs. With a strong scientific foundation and experienced management team, IDRx represents a compelling opportunity in precision oncology, though the early-stage nature and lack of clinical data introduce substantial risk.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1 safety and pharmacokinetic data from lead combination therapy70% success
• Q3 2026Initiation of Phase 2 expansion cohorts in biomarker-selected patient populations55% success
• Q3 2026Presentation of preclinical data and combination rationale at major oncology conference80% success